Abstract
Vitamin D regulates the master iron hormone hepcidin, and iron in turn alters vitamin D metabolism. Although vitamin D and iron deficiency are highly prevalent globally little is known about their interactions in Africa. To evaluate associations between vitamin D and iron status we measured markers of iron status, inflammation, malaria parasitemia and 25-hydroxyvitamin D (25(OH)D) concentrations in 4509 children aged 0.3 months to 8 years living in Kenya, Uganda, Burkina Faso, The Gambia and South Africa. Prevalence of iron deficiency was 35.1%, and preva- lence of vitamin D deficiency was 0.6% and 7.8% as defined by 25(OH)D concentrations of <30 nmol/L and <50 nmol/L respectively. Children with 25(OH)D concentrations of <50 nmol/L had a 98% increased risk of iron deficiency (OR 1.98 [95% CI 1.52, 2.58]) compared to those with 25(OH)D concentrations >75 nmol/L. 25(OH)D concentrations variably influenced individual markers of iron status. Inflammation interacted with 25(OH)D concentrations to predict ferritin levels. The link between vitamin D and iron status should be considered in strategies to manage these nutrient deficiencies in African children.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Wellcome [grant numbers SHA 110255, TNW 202800, AJM 106289 and AME 064693, 079110, 095778], and with core awards to the KEMRI-Wellcome Trust Research Programme [203077]. AA is supported by the Intramural Research Program of the National Institutes of Health in the Center for Research on Genomics and Global Health (CRGGH). The CRGGH (1ZIAHG200362) is supported by the National Human Genome Research Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Center for Information Technology, and the Office of the Director at the National Institutes of Health. RMM is supported through the Developing Excellence in Leadership, Training and Science (DELTAS) Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa Development Planning and Coordinating Agency (NEPAD Agency) with funding from Wellcome [107769] and the UK government. The Gambian work was supported by the UK MRC (U1232661351, U105960371 and MC-A760-5QX00) and DFID under the MRC/DFID Concordat. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome or the UK government. For the purpose of open access, the authors have applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained from all childrens parents or guardians before inclusion in the study. Ethical approvals were granted by the Scientific Ethics Review Unit of the Kenya Medical Research Institute (KEMRI/SERU/CGMR-C/046/3257) in Kenya, the Uganda Virus Research Institute (GC/127/12/07/32) and Uganda National Council for Science and Technology (MV625) in Uganda, by Ministere de la Recherche Scientifique et de lInnovation (reference 2014-12-151) in Burkina Faso, the Gambian Government and the Medical Research Council Ethics Review Committee in The Gambia (874/830), the University of Witwatersrand Human Research Ethics Committee (M130714) in South Africa and in the UK by the London School of Hygiene and Tropical Medicine (A340) and the Oxford Tropical Research Ethics Committees (39-12, 41-12, 42-14, and 1042-13).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Due to heterogeneity between countries, we have performed meta-analyses of country-specific regression estimates instead of pooled regression analyses. To make the manuscript concise and more focused, we have also reserved the summaries of past studies for a future review.
Data Availability
The data and analyses scripts underlying this article are available in Harvard Dataverse at https://doi.org/10.7910/DVN/A78P8B and applications for data access can be made through the Kilifi Data Governance Committee (cgmrc{at}kemri-wellcome.org.
